Core Viewpoint - Kirby McInerney LLP is investigating potential claims against Fortinet, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][3]. Financial Performance - On August 6, 2025, Fortinet reported its Q2 2025 financial results, indicating that it was "approximately 40% to 50% of the way through the 2026 firewall upgrade cycle" based on remaining active units and service contracts [3]. - The company provided weaker than expected revenue guidance for Q3 2025, projecting revenue between $1.67 billion and $1.73 billion [3]. Stock Market Reaction - Following the financial results announcement, Fortinet's share price fell by $21.28, or approximately 22%, from $96.58 on August 6, 2025, to close at $75.30 on August 7, 2025 [4].

Core Insights - AVITA Medical, Inc. is under investigation by Kirby McInerney LLP for potential violations of federal securities laws and unlawful business practices [1][3] - The company's second quarter 2025 financial results revealed a significant backlog in unpaid provider claims for its Recell procedures, which negatively impacted demand [3] - AVITA's share price dropped by approximately 21% following the announcement of the backlog, from $5.38 to $4.25 per share [3] Company Overview - AVITA Medical, Inc. is involved in the development and commercialization of wound care products, specifically the Recell system [3] - The company faced challenges due to contractors from the Centers for Medicare & Medicaid Services failing to timely adjudicate claims and assign appropriate pricing for its products [3] Financial Impact - The backlog of unpaid claims accumulated from January to June 2025, leading to uncertainty among providers and a reduction in Recell utilization during the first half of the year [3] - The decline in share price reflects investor concerns regarding the company's operational challenges and financial health [3]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to alleged violations of federal securities laws, particularly concerning misleading statements about the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application (NDA) for OLC [4][6]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Unicycive between March 29, 2024, and June 27, 2025, to discuss their legal rights [1][4]. - There is a deadline of October 14, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Unicycive [4][9]. - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's readiness to meet FDA manufacturing compliance requirements [6][8]. Group 2: Stock Price Impact - Following a press release on June 10, 2025, regarding FDA deficiencies at a third-party manufacturing vendor, Unicycive's stock price fell by $3.68 per share, or 40.89%, closing at $5.32 [7]. - On June 30, 2025, after the FDA issued a Complete Response Letter for the OLC NDA, citing the same cGMP deficiencies, the stock price dropped by $2.03 per share, or 29.85%, closing at $4.77 [8]. Group 3: Company Background - Unicycive Therapeutics, Inc. is publicly traded on NASDAQ under the ticker UNCY [4]. - Faruqi & Faruqi, LLP has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5].

Core Viewpoint - A class action securities lawsuit has been filed against Fiserv, Inc. alleging securities fraud that negatively impacted investors between July 24, 2024, and July 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Fiserv made false statements regarding its Clover platform, which was forced upon Payeezy merchants due to issues with the older platform [2]. - It is alleged that the revenue growth of Clover was artificially inflated by these conversions, masking a slowdown in new merchant acquisitions [2]. - Following the conversions, many former Payeezy merchants reportedly switched to competitors due to Clover's high pricing and poor customer service [2]. - As a result of these merchant losses, Clover's growth in Gross Payment Volume (GPV) and revenue was said to be unsustainable [2]. - The lawsuit contends that Fiserv's positive statements about Clover's growth strategies and business prospects were materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified period have until September 22, 2025, to request to be appointed as lead plaintiff in the case [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4].

On this news, SelectQuote's stock price fell $0.61, or 19.2%, to close at $2.56 per share on May 1, 2025, on unusually heavy trading volume. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In SelectQuote To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in SelectQuote between September 9, 2020 and May 1, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh ...

Core Insights - Kirby McInerney LLP is investigating potential claims against PubMatic, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][3] - PubMatic reported a significant revenue decline expected in Q3 2025 due to reduced ad spend from a major demand-side platform (DSP) partner [3] Financial Performance - On August 11, 2025, PubMatic disclosed a headwind from a top DSP buyer that shifted clients to a new platform, impacting revenue [3] - Following the announcement, PubMatic's share price fell by $2.23, approximately 21.1%, from $10.57 to $8.34 [3]

Core Viewpoint - A securities class action lawsuit has been filed against CTO Realty Growth, Inc. for allegedly making false and misleading statements regarding its financial health and sustainability of dividends during the class period from February 18, 2021, to June 24, 2025 [1][2]. Group 1: Allegations Against CTO - CTO's dividends were less sustainable than represented, indicating potential misrepresentation of financial stability [6]. - The company allegedly used deceptive practices to inflate Adjusted Funds From Operations (AFFO) and overstated the profitability of its Ashford Lane property [6]. - Public statements made by CTO and its executives were materially false and misleading, leading to investor losses [6]. Group 2: Financial Mismanagement - CTO had not generated sufficient cash to cover recurring capital expenditures and dividends since its 2021 REIT conversion, relying on a 70% increase in shares since December 2022 to offset a $38 million dividend shortfall from 2021 to 2024 [6]. - The company employed a manipulative definition of AFFO by excluding recurring capital expenditures, unlike its peers [6]. - CTO faced an imminent need for further dilution, with only $8.4 million in cash available against $14 million in quarterly dividends and $5.7 million in quarterly recurring capital expenditures [6].

Core Viewpoint - J.M. Smucker Company is facing legal scrutiny and potential claims regarding violations of federal securities laws and other unlawful business practices following disappointing financial results and significant impairment charges related to its Sweet Baked Snacks segment and the Hostess Brand acquisition [1][3][4]. Financial Performance - On November 7, 2023, Smucker announced the acquisition of Hostess Brands for approximately $5.5 billion, with $2.4 billion recorded as goodwill in the Sweet Baked Snacks segment [3]. - For Q3 2025, Smucker reported an 8% decrease in comparable net sales in the Sweet Baked Snacks segment, alongside a $794 million impairment charge related to goodwill and a $208 million impairment charge for the Hostess Brand trademark [3]. - In Q4 2025, the company reported a 14% decrease in comparable net sales in the Sweet Baked Snacks segment, with an additional $867 million impairment charge for goodwill and a $113 million impairment charge for the Hostess Brand trademark [4]. - Following the Q4 results, Smucker's share price fell by $17.44, or approximately 15.59%, closing at $94.41 per share on June 10, 2025 [4]. Strategic Implications - The company has updated its 2026 financial plan to reflect decreased net sales in the Sweet Baked Snacks segment, indicating a sustained underperformance since the acquisition of Hostess Brands [4].

Core Viewpoint - Albany International Corporation is under investigation for potential violations of federal securities laws and unlawful business practices, following disappointing financial results that led to a significant drop in share price [1][3]. Financial Performance - On July 30, 2025, Albany reported non-GAAP earnings per share of $0.57, which was $0.16 below consensus estimates [3]. - The company's President and CEO acknowledged that the financial results "lagged our expectations" due to "certain timing and operational issues" [3]. - Following the earnings announcement, Albany's share price fell by $16.77, or approximately 23.63%, from $70.96 to $54.19 [3]. Legal Investigation - Kirby McInerney LLP is investigating potential claims against Albany and its officers regarding possible violations of federal securities laws [1]. - The law firm is reaching out to individuals who purchased Albany securities or have relevant information to discuss their rights [4]. Law Firm Background - Kirby McInerney LLP specializes in securities, antitrust, whistleblower, and consumer litigation, with a history of achieving recoveries totaling billions of dollars for shareholders [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc. due to allegations of violations of federal securities laws related to misleading statements about the IGNYTE trial and its FDA approval process [4][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Replimune between November 22, 2024, and July 21, 2025, to discuss their legal rights [1][4]. - A federal securities class action has been filed against Replimune, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [4][8]. Group 2: Allegations Against Replimune - The complaint alleges that Replimune and its executives made false and misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [6][7]. - Following the FDA's Complete Response Letter on July 22, 2025, Replimune's stock fell over 73% during intraday trading, indicating significant investor losses [7]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5].